Effect of combined cerulenin/cisplatin treatment on cell viability. Effect of combined cerulenin/cisplatin treatment in the Hey (a) and cisplatin-resistant Heycis
(b) cell lines. Cisplatin was given in various concentrations as a single agent or following administration of 8.75 μmol/L or 17.5 μmol/L cerulenin. As illustrated by the bold black arrows, sequential application of cerulenin for 6 h, followed by 72 h incubation in cisplatin-containing media shifted the cisplatin half maximum inhibitory concentration (IC50) from 2.3 μmol/L to 1.6 μmol/L (30% reduction; P = 0.004) in parental Hey cells and from 14.5 μmol/L to 6.6 μmol/L (54% reduction; P < 0.001) in the cisplatin-resistant Heycis cells.